midazolam has been researched along with Bilateral Headache in 10 studies
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Midazolam nasal spray (MDZ-NS) is indicated for acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern, in patients 12 years of age and older with epilepsy." | 9.34 | Safety and efficacy of midazolam nasal spray for the treatment of intermittent bouts of increased seizure activity in the epilepsy monitoring unit: A double-blind, randomized, placebo-controlled trial. ( Choi, EJ; Cleveland, JM; King, A; Meng, TC; Pullman, WE; Sequeira, DJ; Sinha, SR; Spencer, DC; Van Ess, PJ; Wheless, JW, 2020) |
| "Treatment with midazolam is advisable for headaches in patients with MELAS, in the event that L-arginine therapy is unsuccessful." | 5.40 | [Effectiveness of midazolam for L-arginine-resistant headaches during stroke-like episodes in MELAS: a case report]. ( Hasegawa, Y; Hoshiyama, M; Tsujikawa, K; Yanagi, T; Yasui, K; Yokoi, S, 2014) |
| "Midazolam nasal spray (MDZ-NS) is indicated for acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern, in patients 12 years of age and older with epilepsy." | 5.34 | Safety and efficacy of midazolam nasal spray for the treatment of intermittent bouts of increased seizure activity in the epilepsy monitoring unit: A double-blind, randomized, placebo-controlled trial. ( Choi, EJ; Cleveland, JM; King, A; Meng, TC; Pullman, WE; Sequeira, DJ; Sinha, SR; Spencer, DC; Van Ess, PJ; Wheless, JW, 2020) |
| " Adverse events, oxygen saturation, and vital signs were recorded." | 2.80 | Pharmacokinetics, pharmacodynamics, and safety of USL261, a midazolam formulation optimized for intranasal delivery, in a randomized study with healthy volunteers. ( Bancke, LL; Dworak, HA; Gidal, BE; Halvorsen, MB; Rodvold, KA, 2015) |
| "To add to the evidence base for safe and effective paediatric conscious sedation techniques in primary dental care." | 2.76 | The safety and efficacy of using a concentrated intranasal midazolam formulation for paediatric dental sedation. ( Wood, M, 2011) |
| "Zibotentan (ZD4054) is an oral, specific endothelin A receptor antagonist presently under investigation for the treatment of hormone-resistant prostate cancer." | 2.75 | An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers. ( Kemp, JV; Morris, T; Oliver, SD; Tomkinson, HK; Wollseifen, T, 2010) |
| "She was seizure-free after the surgery." | 1.40 | Peri-ictal headache due to epileptiform activity in a disconnected hemisphere. ( Delalande, O; Dvorak, J; Jahodova, A; Komarek, V; Kršek, P; Kyncl, M; Tichy, M; Vydrova, R, 2014) |
| "Treatment with midazolam is advisable for headaches in patients with MELAS, in the event that L-arginine therapy is unsuccessful." | 1.40 | [Effectiveness of midazolam for L-arginine-resistant headaches during stroke-like episodes in MELAS: a case report]. ( Hasegawa, Y; Hoshiyama, M; Tsujikawa, K; Yanagi, T; Yasui, K; Yokoi, S, 2014) |
| "Withdrawal of midazolam was followed by rebound insomnia, in which sleep latency, total wake time and wake time after sleep onset were increased above baseline." | 1.26 | Sleep laboratory study of the effects of midazolam in insomniac patients. ( Alterwain, P; Altier, H; D'Angelo, L; Debellis, J; Gratadoux, E; Monti, JM, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Spencer, DC | 1 |
| Sinha, SR | 1 |
| Choi, EJ | 1 |
| Cleveland, JM | 1 |
| King, A | 1 |
| Meng, TC | 1 |
| Pullman, WE | 1 |
| Sequeira, DJ | 1 |
| Van Ess, PJ | 1 |
| Wheless, JW | 1 |
| Vydrova, R | 1 |
| Kršek, P | 1 |
| Kyncl, M | 1 |
| Jahodova, A | 1 |
| Dvorak, J | 1 |
| Komarek, V | 1 |
| Delalande, O | 1 |
| Tichy, M | 1 |
| Tsujikawa, K | 1 |
| Yokoi, S | 1 |
| Yasui, K | 1 |
| Hasegawa, Y | 1 |
| Hoshiyama, M | 1 |
| Yanagi, T | 1 |
| Bancke, LL | 1 |
| Dworak, HA | 1 |
| Rodvold, KA | 1 |
| Halvorsen, MB | 1 |
| Gidal, BE | 1 |
| Tomkinson, HK | 1 |
| Kemp, JV | 1 |
| Wollseifen, T | 1 |
| Morris, T | 1 |
| Oliver, SD | 1 |
| Wood, M | 1 |
| Monti, JM | 1 |
| Debellis, J | 1 |
| Gratadoux, E | 1 |
| Alterwain, P | 1 |
| Altier, H | 1 |
| D'Angelo, L | 1 |
| Mainwaring, CJ | 1 |
| Wong, C | 1 |
| Lush, RJ | 1 |
| Smith, JG | 1 |
| Singer, CR | 1 |
| Loeb, P | 1 |
| Adnet, P | 1 |
| Boittiaux, P | 1 |
| Forget, AP | 1 |
| Mille, FX | 1 |
| Sanders, LD | 1 |
| Piggott, SE | 1 |
| Isaac, PA | 1 |
| Okell, RW | 1 |
| Roberts, B | 1 |
| Rosen, M | 1 |
| Robinson, JO | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo Controlled Trial Examining the Safety and Efficacy of Midazolam Intranasal Spray (USL261) for the Treatment of Intermittent Bouts of Increased Seizure Activity in the Epilepsy Monitoring Unit (EMU)[NCT01999777] | Phase 3 | 62 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| A Randomised, Open-label, Crossover, Phase I Study to Assess the Effect of Multiple Oral Doses of ZD4054 (Zibotentan) on the Pharmacokinetics of a CYP450 3A Probe (Midazolam) in Healthy Male Subjects[NCT00709553] | Phase 1 | 12 participants (Anticipated) | Interventional | 2008-07-31 | Completed | ||
| Comparison of Three Different Pain and Anxiety Reducing Methods in Adult Patients Undergoing Bone Marrow Puncture[NCT00188227] | Phase 4 | 748 participants | Interventional | 2001-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"A participant was considered seizure-free if he or she completed the 6-hour Treatment Phase without seizures recorded, premature discontinuation of study drug, rescue intervention for acute central respiratory depression adverse event (AE), and alterations to background anti-epileptic drug (AED) therapy. Otherwise, the participant was included in the analysis for seizure-free events with the outcome of seizure." (NCT01999777)
Timeframe: 6 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| USL261 | 17 |
| Placebo | 12 |
Time to first seizure following treatment was defined as time from treatment with study drug to the onset of the next seizure, rescue intervention (for acute central respiratory depression AE) to maintain subject safety, alterations to background AED therapy, early termination, or 6 hours, whichever came first. (NCT01999777)
Timeframe: 6 hours
| Intervention | hours (Median) |
|---|---|
| USL261 | NA |
| Placebo | 3.9 |
5 trials available for midazolam and Bilateral Headache
| Article | Year |
|---|---|
Safety and efficacy of midazolam nasal spray for the treatment of intermittent bouts of increased seizure activity in the epilepsy monitoring unit: A double-blind, randomized, placebo-controlled trial.
Topics: Administration, Intranasal; Adolescent; Adult; Anticonvulsants; Child; Double-Blind Method; Epilepsy | 2020 |
Pharmacokinetics, pharmacodynamics, and safety of USL261, a midazolam formulation optimized for intranasal delivery, in a randomized study with healthy volunteers.
Topics: Administration, Intranasal; Adolescent; Adult; Chemistry, Pharmaceutical; Cross-Over Studies; Dose-R | 2015 |
An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers.
Topics: Adult; Anti-Anxiety Agents; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome | 2010 |
The safety and efficacy of using a concentrated intranasal midazolam formulation for paediatric dental sedation.
Topics: Administration, Intranasal; Adolescent; Anesthesia, Dental; Anesthetics, Local; Child; Child Behavio | 2011 |
Reversal of benzodiazepine sedation with the antagonist flumazenil.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Anesthesia Recovery Period; Anesthesia, Intravenous; Benzo | 1991 |
5 other studies available for midazolam and Bilateral Headache
| Article | Year |
|---|---|
Peri-ictal headache due to epileptiform activity in a disconnected hemisphere.
Topics: Anticonvulsants; Brain; Carbamazepine; Child, Preschool; Electroencephalography; Epilepsy; Female; F | 2014 |
[Effectiveness of midazolam for L-arginine-resistant headaches during stroke-like episodes in MELAS: a case report].
Topics: Adolescent; Anesthetics, Intravenous; Arginine; DNA, Mitochondrial; Drug Resistance; Electroencephal | 2014 |
Sleep laboratory study of the effects of midazolam in insomniac patients.
Topics: Adult; Benzodiazepines; Drug Evaluation; Female; Headache; Humans; Male; Midazolam; Middle Aged; Sle | 1982 |
The role of midazolam-induced sedation in bone marrow aspiration/trephine biopsies.
Topics: Adolescent; Adult; Aged; Anesthetics, Local; Antidotes; Awareness; Bone Marrow; Conscious Sedation; | 1996 |
[Benzodiazepine withdrawal presenting as pseudo-surgical abdominal pain].
Topics: Abdomen, Acute; Adult; Alprazolam; Anti-Anxiety Agents; Bromazepam; Diagnosis, Differential; Headach | 1997 |